Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2023 | A brief background on neoantigen vaccines

Mansi Saxena • 16 Apr 2023
AACR 2023
General PGV_001

Mansi Saxena, PhD, Icahn School of Medicine at Mount Sinai, New York, NY, gives an overview of the development of neoantigen vaccines. Neoantigens, antigens exclusively expressed on tumors, enable immune evasion in tumors. Whilst previous trials assessing neoantigen vaccines have taken place, the Phase I trial (NCT02721043) investigating the PGV_001 neoantigen vaccine will have a broader inclusion criteria. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Mansi Saxena

1:29
Challenges and barriers to using cancer vaccines in the clinic
Mansi Saxena • 16 Apr 2023
4:48
PGV_001, a neoantigen vaccine, produces promising immune responses
Mansi Saxena • 16 Apr 2023

Related Videos

2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals